FindTrial
Sign In

A prospective comparative study of pharmacoeconomics and patient compliance between short-acting G-CSF and PEG-CSF in primary prevention of neutropenia after adjuvant chemotherapy for breast cancer patients

A prospective comparative study of pharmacoeconomics and patient compliance between short-acting G-CSF and PEG-CSF in primary prevention of neutropenia after adjuvant chemotherapy for breast cancer patients

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000037800
Enrollment
Unknown
Registered
2020-09-02
Start date
2020-09-01
Completion date
Unknown
Last updated
2020-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

Group 1:short-acting G-CSF
Group 2:PEG-G-CSF

Sponsors

The First Affiliated Hospital, Sun Yat-sen University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Confirmed breast cancer by histopathology or cytology; 2. Adjuvant chemotherapy, and chemotherapy regimen with median-high risk of neutropenia; 3. Willing to follow up regularly and complete research projects; 4. Normal heart, liver and kidney function.

Exclusion criteria

Exclusion criteria: 1. Chemotherapy regimens with low-risk neutropenia; 2. Previous hematopoietic stem cell transplantation or organ transplantation; 3. Infection or blood system disease that is difficult to control; 4. Poor compliance, unwilling to follow up, unable to complete the required research projects.

Design outcomes

Primary

MeasureTime frame
scores of each dimension in FACT-B;scores of economics analysis questionnaire;—

Countries

China

Contacts

Public ContactJie Li

The First Affiliated Hospital, Sun Yat-sen University

lijie78@mail.sysu.edu.cn+86 13602790063

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026